New drug reduces protein in urine for patients with IgA nephropathy

A phase 3 trial shows povetacicept significantly lowers urinary protein and galactose-deficient IgA1 levels.

A drug called povetacicept reduced protein in the urine of people with IgA nephropathy. In a trial, the 24-hour urinary protein-to-creatinine ratio decreased by 52.0%52.0\% with povetacicept. The placebo group saw only a 4.3%4.3\% decrease by week 36.

Researchers conducted a phase 3, double-blind, placebo-controlled trial. Participants with biopsy-proven IgA nephropathy were assigned to receive povetacicept or a placebo. The drug was given subcutaneously every 4 weeks.

The drug is an enhanced, variant transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fragment fusion therapeutic. It is engineered for dual inhibition of BAFF and APRIL. BAFF and APRIL are proteins that play roles in IgA-producing B-cell populations.

Galactose-deficient IgA1 levels decreased by 77.4%77.4\% with povetacicept. Among participants with baseline hematuria, resolution occurred in 85%85\% with povetacicept and 23%23\% with placebo. The incidence of serious adverse events was 3%3\% for povetacicept and 4%4\% for placebo.

Key facts

  • The 24-hour urinary protein-to-creatinine ratio decreased by 52.0%52.0\% with povetacicept.
  • Galactose-deficient IgA1 levels decreased by 77.4%77.4\% with povetacicept.
  • Resolution of hematuria occurred in 85%85\% of povetacicept participants with baseline hematuria.

All sections

Edition